Information Provided By: 
Fly News Breaks for February 6, 2017
CYTK
Feb 6, 2017 | 07:57 EDT
As previously reported, Needham analyst Chad Messer upgraded Cytokinetics to Strong Buy from Buy ahead of pivotal Tirsemtiv data and multiple other drivers. The analyst also raised his price target to $22 from $17.
News For CYTK From the Last 2 Days
CYTK
Apr 26, 2024 | 16:10 EDT
In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has agreed to serve as the company's Executive Vice President, CFO, effective as of May 8. On the start date, Lee will assume the duties and responsibilities of the company's principal financial officer from Robert Blum, the company's President and CEO, who has been serving as the company's principal financial officer on an interim basis
